[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8](=[O:24])[NH:9][CH2:10][C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][C:12]=2[N:17]2[CH2:22][CH2:21][N:20]([CH3:23])[CH2:19][CH2:18]2)=[CH:4][C:3]=1[NH:25][C:26]([C:28]1[N:32]2[CH:33]=[CH:34][C:35]([C:37]3[CH:38]=[N:39][N:40]([CH3:42])[CH:41]=3)=[CH:36][C:31]2=[N:30][CH:29]=1)=[O:27].[ClH:43].CCOCC>CO>[ClH:43].[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8](=[O:24])[NH:9][CH2:10][C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][C:12]=2[N:17]2[CH2:18][CH2:19][N:20]([CH3:23])[CH2:21][CH2:22]2)=[CH:4][C:3]=1[NH:25][C:26]([C:28]1[N:32]2[CH:33]=[CH:34][C:35]([C:37]3[CH:38]=[N:39][N:40]([CH3:42])[CH:41]=3)=[CH:36][C:31]2=[N:30][CH:29]=1)=[O:27]N-(2-Fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (step 1) (30 mg, 0.053 mmol) in MeOH (2 ml) was treated with HCl in ether (0.053 ml, 0.053 mmol) and the solution was evaporated to dryness and dried in vacuo overnight to afford the title compound; LC-MS: Rt 0.82 mins; MS m/z 56, [M+H]+; Method 2minLC_v003
Wird geladen…